SCHEMBL21363462

SCHEMBL21363462

CC(C)(C)c1ccc(CC(C)(C)c2ccc3ncsc3c2)cc1F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 2/20 0.36
NTRK2 Q16620 2/20 0.36
MEN1 O00255 4/20 0.35
KMT2A Q03164 4/20 0.35
POLB P06746 2/20 0.35
NPC1 O15118 7/20 0.34
RAB9A P51151 7/20 0.34
TGFBR1 P36897 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
KDM4E B2RXH2 2/20 0.33
HKDC1 Q2TB90 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
ALDH1A1 P00352 1/20 0.33
TAS1R3 Q7RTX0 1/20 0.33
TAS1R1 Q7RTX1 1/20 0.33
GSK3B P49841 1/20 0.32
CFTR P13569 1/20 0.32
PFKFB3 Q16875 1/20 0.32
KDR P35968 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22210484 0.84 CYP3A4 (0.34) NTRK1NTRK2MEN1KMT2APOLB
SCHEMBL26879793 0.76 ESR1 (0.44) APP
SCHEMBL21191692 0.75 ESR1 (0.43) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL8203530 0.73 NPC1 (0.42) NTRK1NTRK2MEN1KMT2APOLB
SCHEMBL23479624 0.73 NTRK1 (0.34) NTRK1NTRK2MEN1KMT2APOLB
SCHEMBL761993 0.73 MEN1 (0.52) NTRK1NTRK2MEN1KMT2APOLB
SCHEMBL20354335 0.72 NPC1 (0.44) NTRK1NTRK2MEN1KMT2APOLB
SCHEMBL23418541 0.70 TGFBR1 (0.41) NTRK1NTRK2MEN1KMT2APOLB
SCHEMBL22141995 0.70 TRPV1 (0.33) NPC1RAB9A
SCHEMBL26577865 0.69 ESR1 (0.41) ALDH1A1APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11655245-B2 Oxadiazole transient receptor potential channel inhibitors GENENTECH, INC. (US) 2023-05-23 US disclosed
US-20230121700-A1 OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS GENENTECH, INC. (US) 2023-04-20 US disclosed
US-20200308161-A1 OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS GENENTECH, INC. (US) 2020-10-01 US disclosed
US-10710994-B2 Oxadiazole transient receptor potential channel inhibitors GENENTECH, INC. (US) 2020-07-14 US disclosed
US-20190284179-A1 OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS GENENTECH, INC. (US) 2019-09-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11655245-B2 Oxadiazole transient receptor potential channel inhibitors TRPA1, TRPV1, P2RX3 NTRK1 890/4885NTRK2 1388/4885MEN1 4288/4885
US-20190284179-A1 OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS TRPA1, TRPV1, TRPV3 NTRK1 774/4885NTRK2 1196/4885MEN1 4165/4885
US-20200308161-A1 OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS TRPA1, TRPV1, P2RX3 NTRK1 890/4885NTRK2 1388/4885MEN1 4288/4885
US-10710994-B2 Oxadiazole transient receptor potential channel inhibitors TRPA1, TRPV1, TRPV3 NTRK1 774/4885NTRK2 1196/4885MEN1 4165/4885
US-20230121700-A1 OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS TRPA1, TRPV1, TRPV3 NTRK1 774/4885NTRK2 1196/4885MEN1 4165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.